149503-79-7
Chemical Structure
Lefradafiban
Synonym(s): BIBU-104
- CAS No.: 149503-79-7
- Formula:C23H25N3O6
- Molecular Weight:439.46
IUPAC Name: methyl 2-((3S,5S)-5-(((4'-(N-(methoxycarbonyl)carbamimidoyl)-[1,1'-biphenyl]-4-yl)oxy)methyl)-2-oxopyrrolidin-3-yl)acetate
InChIKey: PGCFXITVMNNKON-ROUUACIJSA-N
SMILES: N=C(C(C=C1)=CC=C1C(C=C2)=CC=C2OC[C@H]3NC([C@H](CC(OC)=O)C3)=O)NC(OC)=O
Biological Activity: Lefradafiban (BIBU-104) is an orally effective glycoprotein IIb/IIIa receptor blocker. The active metabolite of Lefradafiban, Fradafiban (HY-101720), blocks the platelet glycoprotein IIb/IIIa receptor and inhibits fibrinogen-mediated platelet aggregation. Lefradafiban can be used in research on stable coronary artery disease, unstable angina, or myocardial infarction[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lefradafiban | 98.92% | Lefradafiban (BIBU-104) is an orally effective glycoprotein IIb/IIIa receptor blocker. The active metabolite of Lefradafiban, Fradafiban (HY-101720), blocks the platelet glycoprotein IIb/IIIa receptor and inhibits fibrinogen-mediated platelet aggregation. Lefradafiban can be used in research on stable coronary artery disease, unstable angina, or myocardial infarction. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Akkerhuis KM, et al. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart (British Cardiac Society). 2001 Apr;85(4):444-50. [Content Brief]
- [2]. Chong PH, et al. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 1998 Nov 15;55(22):2363-86.
